Skip to content

FDA Advisory Committee Recommends Novartis’ Orphan Drug Signifor (Pasireotide) For Cushing’s Disease

November 8, 2012

       On November 7, 2012, the FDA Endocrinologic and Metabolic Drug Advisory Committee (EMDAC) unanimously votes 10-0 in favor of the injectable orphan drug Signifor (Pasireotide) for the treatment of Cushing’s Disease. Signifor is the 1st drug to treat Cushing’s Disease in the US. The drug is already approved for Cushing’s Disease in Europe.


FDA Orphan Drug Product Database Record for Pasireotide   

Novartis November 7, 2012 News Release  

Orphan Druganaut November 7, 2012 Blog Post titled, “November 2012 FDA Advisory Committee Meetings Involving Orphan Drugs”  

Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: